Skip to content
Catalyst

PapersPMID:38542695

The Effects of Cranberry Consumption on Glycemic and Lipid Profiles in Humans: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Nutrients2024The record ↗

findings
7
compound
1
endpoints
7
no difference found
6
PMID:38542695
  1. Finding, moderate evidencelowersHOMA-IR
  2. Finding, moderate evidenceno difference foundFasting blood glucose
  3. Finding, moderate evidenceno difference foundGlycated haemoglobin (HbA1c)
  4. Finding, moderate evidenceno difference foundTotal cholesterol (TC)
  5. Finding, moderate evidenceno difference foundHDL cholesterol
  6. Finding, moderate evidenceno difference foundLDL cholesterol
  7. Finding, moderate evidenceno difference foundTriglycerides
Study, every finding
meta-analysis
Dose studied, every finding
Pooled doses: capsules or tablets 144 to 1500 mg/day, powder 9 g/day, juice 240 to 750 mL/day; intervention length 2 weeks to 6 months
  • “In terms of glycemic indicators, HOMA-IR was investigated in five studies, and the pooled estimates suggested that cranberry significantly reduced HOMA-IR (MD = −0.59; 95% CI: −1.05, −0.14; peffect = 0.01; Figure 4D), whereas cranberry supplementation did not show significant alterations to FBG (MD = −0.09; 95% CI: −0.23, 0.04; peffect = 0.17), HbA1c (MD = −0.16; 95% CI: −0.38, 0.05; peffect = 0.13), and fasting insulin (MD = −1.31; 95% CI: −2.85, 0.22; peffect = 0.09).”
    Effect
    −0.59 mean difference, 95% CI −1.05 to −0.14
    Population
    Adults aged 18 to 80 in randomized placebo-controlled trials of cranberry supplementation (healthy people and patients with overweight or obesity, diabetes, cardiovascular disease, metabolic syndrome or non-alcoholic fatty liver); pooled estimate from five studies

What did not

  • “However, no significant decrease or increase was observed between cranberry supplementation and other blood lipid profiles: TC (MD = −0.11; 95% CI: −0.26, 0.03; peffect = 0.12), HDL-C (MD = −0.02; 95% CI: −0.05, 0.01; peffect = 0.25), LDL-C (MD = −0.10; 95% CI: −0.20, 0.01; peffect = 0.07), and TG (MD = 0.06; 95% CI: 0.00, 0.12; peffect = 0.05).”
    • Effect
      −0.11 mean difference, 95% CI −0.26 to 0.03
      Population
      Adults aged 18 to 80 in randomized placebo-controlled trials of cranberry supplementation (healthy people and patients with overweight or obesity, diabetes, cardiovascular disease, metabolic syndrome or non-alcoholic fatty liver); pooled estimate
    • Effect
      −0.02 mean difference, 95% CI −0.05 to 0.01
      Population
      Adults aged 18 to 80 in randomized placebo-controlled trials of cranberry supplementation (healthy people and patients with overweight or obesity, diabetes, cardiovascular disease, metabolic syndrome or non-alcoholic fatty liver); pooled estimate
    • Effect
      −0.1 mean difference, 95% CI −0.2 to 0.01
      Population
      Adults aged 18 to 80 in randomized placebo-controlled trials of cranberry supplementation (healthy people and patients with overweight or obesity, diabetes, cardiovascular disease, metabolic syndrome or non-alcoholic fatty liver); pooled estimate
    • Effect
      0.06 mean difference, 95% CI 0 to 0.12
      Population
      Adults aged 18 to 80 in randomized placebo-controlled trials of cranberry supplementation (healthy people and patients with overweight or obesity, diabetes, cardiovascular disease, metabolic syndrome or non-alcoholic fatty liver); pooled estimate

Study record

Design
meta-analysis
Species
human
Population
adults aged 18 to 80 in 16 randomized controlled trials of cranberry supplementation (healthy, overweight or obesity, diabetes, CVD, metabolic syndrome, NAFLD)
Participants
708
Comparator
placebo
Duration
not reported
Endpoints measured
10